Investor Relations

Theralink Technologies is a Precision Medicine company that provides personalized medicine data through its Theralink assays, Theralink is the leading developer of phosphoproteomic technologies for measuring the activation state of key drug targets and signaling pathways, with applications across multiple cancer types, including breast, non-small cell lung, ovarian, liver, prostate, gastric, brain, kidney, colorectal and pancreatic. Theralink was developed to empower physicians with potentially actionable information missed entirely by genomics assays to help them make time-sensitive treatment decisions for their patients. Theralink was designed to provide new predictive biomarkers through the direct measurement of drug target activation mapping, making Theralink instrumental in the development of molecular targeted therapies. The information gathered through measurement of protein and phosphoprotein markers has the potential to help physicians make molecularly rationalized treatment decisions that might improve treatment outcomes and may reduce side effects by foregoing ineffective therapy.